BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10380832)

  • 1. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex.
    Lukinius A; Ohrvall U; Westlin JE; Oberg K; Tiensuu Janson E
    Acta Oncol; 1999; 38(3):383-7. PubMed ID: 10380832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.
    Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H
    J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
    Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE; McLean SF; Kirkman RL; Della Manna D; Bright SJ; Olsen CC; Myracle AD; Mayo MS; Curiel DT; Buchsbaum DJ
    Clin Cancer Res; 1999 Feb; 5(2):383-93. PubMed ID: 10037188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
    Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors.
    Nilsson O; Kölby L; Bernhardt P; Forssell-Aronsson E; Johanson V; Ahlman H
    Ann N Y Acad Sci; 2004 Apr; 1014():275-9. PubMed ID: 15153445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
    Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
    Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radioactive somatostatin and its analogues in the control of tumor growth.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
    Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
    Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.
    Tiensuu Janson E; Eriksson B; Oberg K; Skogseid B; Ohrvall U; Nilsson S; Westlin JE
    Acta Oncol; 1999; 38(3):373-7. PubMed ID: 10380830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.